586412-87-5Relevant academic research and scientific papers
TYK2 INHIBITORS AND USES THEREOF
-
, (2020/09/27)
Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors
Lovell, Peter J.,Blaney, Frank E.,Goodacre, Caroline J.,Scott, Claire M.,Smith, Paul W.,Starr, Kathryn R.,Thewlis, Kevin M.,Vong, Antonio K.K.,Ward, Simon E.,Watson, Jeannette M.
, p. 1033 - 1036 (2007/10/03)
Investigation of halogen substitution in lead compound 1 has led to the identification of analogues which combine high affinity for 5-HT1A receptors and potent serotonin reuptake inhibitory activity. Several compounds show an improved selectivity over 5-HT1B and 5-HT1D receptors and a superior pharmacokinetic profile in the rat.
BENZOXAZINONE DERIVATIVE
-
Page/Page column 9, (2010/02/07)
The compound 6-(4-(1-(2-(5-(7-Fluoro-2-methyl)quinolinyloxy)ethyl)piperidinyl)methyl)-7-fluoro-4H-benzo[1,4]oxazin-3-one and pharmaceutically acceptable salts thereof are disclosed. Methods of preparation and use in therapy, particularly for a CNS disorde
